- Home
- AMLX vs NVCR Comparison
AMLX vs NVCR Comparison
Compare AMLX & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMLX | NVCR |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | AMLX | NVCR |
|---|---|---|
| Price | $13.90 | $10.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | $20.11 | ★ $28.08 |
| AVG Volume (30 Days) | 867.2K | ★ 1.2M |
| Earning Date | 03-03-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.46 | 21.79 |
| EPS | N/A | ★ N/A |
| Revenue | $380,786,000.00 | ★ $655,353,000.00 |
| Revenue This Year | N/A | $7.72 |
| Revenue Next Year | N/A | $6.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1612.94 | 8.28 |
| 52 Week Low | $3.11 | $9.82 |
| 52 Week High | $17.49 | $20.05 |
Technical Indicators
Market Signals| Indicator | AMLX | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 48.61 | 40.06 |
| Support Level | $13.36 | N/A |
| Resistance Level | $15.37 | $13.59 |
| Average True Range (ATR) | 0.74 | 0.58 |
| MACD | -0.08 | -0.18 |
| Stochastic Oscillator | 48.17 | 23.02 |
Price Performance
Historical ComparisonAbout AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.